» Articles » PMID: 26746689

S-1 and Irinotecan Plus Bevacizumab As Second-line Chemotherapy for Patients with Oxaliplatin-refractory Metastatic Colorectal Cancer: a Multicenter Phase II Study in Japan (KSCC1102)

Abstract

Background: Combination chemotherapy with S-1 and irinotecan is one of the standard treatments for metastatic colorectal cancer (mCRC) in Japan. However, there are few alternative practical second-line therapies. We conducted a phase II trial to evaluate the efficacy and safety of the combination of S-1 and irinotecan plus bevacizumab as a second-line treatment for oxaliplatin-refractory mCRC.

Methods: Patients with mCRC who were previously treated with oxaliplatin-containing regimens were enrolled. Oral S-1 at a dose of 40 mg/m(2) was administered twice daily for 2 weeks, followed by a 1-week drug-free interval. Irinotecan at a dose of 150 mg/m(2) and bevacizumab at a dose of 7.5 mg/kg were administered on day 1. The primary endpoint was progression-free survival (PFS).

Results: Thirty-seven patients were enrolled, and 34 and 36 patients were assessed for response and safety, respectively. The overall response rate was 20.6 % (95 % confidence interval [CI] 8.7-37.9), and the disease control rate was 76.5 % (95 % CI 58.8-89.3). The median PFS was 5.6 months (95 % CI 3.8-7.0). The median overall survival was 16.4 months (95 % CI 8.1-20.0). The most common grade 3/4 adverse events included neutropenia (25.0 %), anorexia (22.2 %), anemia (16.7 %), and fatigue/malaise (16.7 %). The most common grade 3/4 adverse event of special interest for bevacizumab was hypertension (30.6 %). One treatment-related death caused by gastrointestinal bleeding occurred.

Conclusions: The findings suggest that the combination of S-1 and irinotecan plus bevacizumab is effective and tolerable as second-line chemotherapy for patients with oxaliplatin-refractory mCRC.

Citing Articles

A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer.

Higami S, Mukai M, Yokoyama D, Uda S, Abe R, Mamuro N J Gastrointest Oncol. 2023; 14(2):663-675.

PMID: 37201062 PMC: 10186548. DOI: 10.21037/jgo-22-899.


FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial.

Zhang X, Duan R, Wang Y, Liu X, Zhang W, Zhu X Ther Adv Med Oncol. 2022; 14:17588359211068737.

PMID: 35069808 PMC: 8771434. DOI: 10.1177/17588359211068737.

References
1.
Shiozawa M, Akaike M, Sugano N, Tsuchida K, Yamamoto N, Morinaga S . A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2010; 66(5):987-92. DOI: 10.1007/s00280-010-1278-0. View

2.
Suenaga M, Nishina T, Mizunuma N, Yasui H, Ura T, Denda T . Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802). BMC Cancer. 2015; 15:176. PMC: 4376520. DOI: 10.1186/s12885-015-1175-3. View

3.
Yamada Y, Yamaguchi T, Matsumoto H, Ichikawa Y, Goto A, Kato K . Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Invest New Drugs. 2011; 30(4):1690-6. DOI: 10.1007/s10637-011-9743-0. View

4.
Yoshioka T, Gamoh M, Chiba N, Suzuki T, Sakayori N, Kato S . Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. Br J Cancer. 2009; 101(12):1972-7. PMC: 2795445. DOI: 10.1038/sj.bjc.6605432. View

5.
Tabernero J, Yoshino T, Lee Cohn A, Obermannova R, Bodoky G, Garcia-Carbonero R . Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised,.... Lancet Oncol. 2015; 16(5):499-508. DOI: 10.1016/S1470-2045(15)70127-0. View